# InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection FR BL Cohort

> **NCT04407689** · PHASE2 · TERMINATED · sponsor: **Revimmune** · enrollment: 34 (actual)

## Conditions studied

- COVID-19
- Lymphocytopenia

## Interventions

- **DRUG:** Interleukin-7
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04407689
- **Lead sponsor:** Revimmune
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-06-08
- **Primary completion:** 2022-03-30
- **Final completion:** 2022-03-30
- **Target enrollment:** 34 (ACTUAL)
- **Why stopped:** poor accrual
- **Last updated:** 2022-04-08

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04407689

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04407689, "InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection FR BL Cohort". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04407689. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*